Steris Plc 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Steris Plc on October 2, 2020, with the earliest event reported on that same date. The filing primarily announces the entry into a material definitive agreement to acquire Key Surgical LLC, a global provider of sterile processing, operating room, and endoscopy consumable products serving hospitals and surgical facilities.
Key Financial Metrics and Transaction Details
- Transaction Value: The purchase price for the acquisition of Key Surgical is $850.0 million in cash.
- Net Cost: Approximately $810.0 million net of tax benefits, subject to customary adjustments.
- Debt Assumption: Steris is not assuming any debt of the target company.
- Funding Source: The transaction is intended to be funded through a combination of debt and cash on hand.
- Financial Performance: This filing does not provide specific revenue, profit, cash flow, margin, or liquidity metrics for Steris Plc for the current or prior periods.
Material Changes and Conditions
The primary material change is the pending acquisition of Key Surgical. The completion of the transaction is subject to the satisfaction or waiver of customary conditions, including the receipt of requisite Hart-Scott-Rodino Act approvals. The agreement includes customary representations, warranties, covenants, and confidentiality, non-solicitation, and non-compete obligations for the sellers and restricted parties.
Outlook, Risks, and Contingencies
Management has identified several risks and contingencies that could affect the transaction and future performance:
- Transaction Completion: Risks include the inability to fulfill closing conditions or obtain financing on satisfactory terms.
- Integration and Benefits: There is a possibility that anticipated financial results or benefits from the acquisition will not be realized.
- Macro and Regulatory Risks: Risks include the impact of the COVID-19 pandemic, changes in tax laws (including the Tax Cuts and Jobs Act), regulatory actions by the FDA or EPA, international unrest, Brexit, and contractions in credit availability.
- Operational Risks: Potential for increased operating costs, customer loss, or business disruption following the company's redomiciliation to Ireland.
Key Facts for Investor Verification
- Verify the final closing date and whether all regulatory conditions, specifically Hart-Scott-Rodino approvals, have been met.
- Confirm the final purchase price after customary adjustments and the specific mix of debt versus cash used for funding.
- Monitor future filings for the impact of the acquisition on Steris's consolidated financial statements and debt covenants.
- Review subsequent reports for updates on the realization of anticipated tax benefits and synergies from the Key Surgical acquisition.